TABLE 1.
Antibody responsesa
| Mice | Mean titerb of:
|
||||||
|---|---|---|---|---|---|---|---|
| Serum IgG1 | Serum IgG2a | BALF IgA | BALF IgG1 | BALF IgG2a | Serum neut.c | BALF neut.c | |
| Controls | |||||||
| 28 days | >1.8 × 104 (≥1.8 × 104; 4/4) | >1.8 × 104 (≥1.8 × 104; 4/4) | 156 (30–810; 4/4) | 270 (30–810; 4/4) | 1.4 × 103 ([0.3–7.3] × 103; 4/4) | 136 (16,256; 2/2) | 32 (16,64; 2/2) |
| 90–102 days | 4.2 × 103 ([2.0–6.1] × 103; 3/3) | >1.8 × 104 (≥1.8 × 104; 3/3) | 11.4 (5–30; 2/3) | 30.0 (10–90; 2/3) | 562 (0.3–2.4 × 103; 3/3) | 64 (64; n = 1) | <4 (<4; n = 1) |
| 21 days post 2°; 119–136 days post 1° | >1.8 × 104 (≥1.8 × 104; 2/2) | >1.8 × 104 (≥1.8 × 104; 2/2) | 1.4 × 103 ([0.3–7.9] × 103; 2/2) | 1.4 × 103 ([0.3–7.9] × 103; 2/2) | 1.4 × 103 ([0.3–7.9] × 103; 2/2) | NDd | ND |
| Combined treatment | |||||||
| 28 days post 1° | 13.8 (<25–25; 1/6) | 25.9 (<25–2,025; 1/6) | 8.1 (<10–10; 1/6) | 5.6 (<10–270; 1/6) | 9.7 (<10–90; 1/6) | <16 (<16; 0/2) | <4 (<4; 0/2) |
| 90–102 days post 1° | 98.5 (<25–2.0 × 103; 5/7) | 3.8 × 103 (75–1.8 × 104; 7/7) | 28.8 (<10–810; 5/7) | 11.9 (<10–270; 4/7) | 118 (<10–2,430; 5/7) | 5.3 (<16–16; 1/3) | <4 (<4; 0/3) |
| 21 days post 2°; 119– 136 days post 1° | 276 (<25, 6.1 × 103; 1/2) | 272 (<25, 1.8 × 104; 1/2) | 1.4 × 103 ([0.3–7.9] × 103; 2/2) | 270 (90, 810; 2/2) | 4.2 × 103 ([2.4–7.3] × 103; 2/2) | ND | ND |
a
Isotype-specific anti-adenoviral antibodies were assayed by ELISA on a subset of the mice in the experiments in Fig. 2 and 4; control mice were either treated with the control monoclonal antibody L6 or not treated, with similar results. The combined-treatment group received systemic muCTLAIg and MR1 and intratracheal Ad.RSV-muCTLA4Ig with the primary vector and intratracheal Ad.RSVmuCTLA4Ig with the secondary vector.
b
Geometric mean titer (range; number of mice with detectable antibody/number tested).
c
The 90- to 102-day neutralizing antibody titers were determined 3 days after secondary vector administration.
d
ND, not done.